Solid Biosciences Reports Positive Interim Phase 1/2 Data for SGT-003 in Duchenne Muscular Dystrophy, Aligns with FDA on Phase 3 Design

summarizeSummary

Solid Biosciences announced positive interim Phase 1/2 clinical data for SGT-003 in Duchenne muscular dystrophy, demonstrating robust microdystrophin expression and biomarker improvements, alongside alignment with the FDA on Phase 3 trial design.

check_boxKey Events

• Positive Interim Clinical Data for SGT-003

  The company reported positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. Data as of February 23, 2026, showed SGT-003 was generally well tolerated in 40 participants.

• Robust Microdystrophin Expression and Biomarker Improvements

  Biopsy results from 20 participants at Day 90 showed mean microdystrophin expression of 60% by western blot and 52% by mass spectroscopy. Significant improvements were observed in muscle integrity biomarkers, including a mean 44% reduction in embryonic myosin heavy chain (eMHC)-positive fibers at Day 90, suggesting disruption of the degeneration-regeneration cycle.

• Cardiac Function Stabilization

  Cardiac assessments showed stabilization-to-improvement in systolic function, as measured by left ventricular ejection fraction (LVEF), particularly in participants with low-normal baseline LVEF.

• FDA Alignment on Phase 3 Trial Design

  Solid Biosciences has reached alignment with the FDA on the overall study design for its randomized, double-blind, placebo-controlled Phase 3 IMPACT DUCHENNE clinical trial for SGT-003. Participant screening is underway, with the first participant dosing anticipated in Q1 2026.

auto_awesomeAnalysis

This 8-K filing provides detailed positive interim clinical data for Solid Biosciences' lead gene therapy candidate, SGT-003, in Duchenne muscular dystrophy. The robust microdystrophin expression, significant reductions in muscle damage biomarkers, and stabilization of cardiac function are strong indicators of therapeutic effect. The alignment with the FDA on the Phase 3 trial design and ongoing discussions for an accelerated approval pathway significantly de-risk the program and provide a clear path forward for this critical asset. This data could be a major catalyst for the company, especially following recent capital raises.